Hezhe Lu, Hui Yang, Zhexin Ding, Zhuoling An, Yong Zhao
BACKGROUND: Immune checkpoint inhibitors (ICIs) hold promise as treatment options for various types of cancer. However, recent case reports have brought attention to myositis, a potentially life-threatening complication associated with ICIs. This study aims to assess the spectrum of myositis associated with ICIs, including its clinical features, risk factors for fatal cases, adverse events (AEs) accompanying ICIs-related myositis, and the risk of myositis in different populations in real-world settings...
April 17, 2024: Expert Opinion on Drug Safety
Dipika Bansal, Beema T Yoosuf, Muhammed Favas Kt, Pinaki Dutta
BACKGROUND: Dipeptidyl peptidase-4 inhibitors (DPP-4 inhibitors) have acquired a foothold in managing type 2 diabetes mellitus, but few concerns have arisen regarding their overall safety profile. The aim of this study is to assess the potential risk of DPP-4 inhibitors by analyzing data from the FDA Adverse Event Reporting System (FAERS) database. RESEARCH DESIGN AND METHODS: This is a retrospective study which explored the FAERS database till March 2023 for the collection of safety reports...
April 16, 2024: Expert Opinion on Drug Safety
Jinhua Chen, Weijiang Yu, Wancun Zhang, Cuicui Sun, Wenzhou Zhang
BACKGROUND: Evaluating antibiotics most commonly associated with pseudomembranous colitis (PMC) based on the real-world data is of great significance. RESEARCH DESIGN AND METHODS: We used the data from FAERS to evaluate the potential association between antibiotics and PMC by disproportionality analyzes. RESULTS: Eighty-one antibiotics which met the three algorithms simultaneously were enrolled. There were 1683 reports of PMC associated with the enrolled antibiotics...
April 11, 2024: Expert Opinion on Drug Safety
Mengjia Ying, Jian Shi, Yahao Ling, Tao Shi, Lele Liao, Linhui Cao
BACKGROUND: Lanthanum carbonate is widely used to manage serum phosphate and calcium levels in end-stage kidney disease (ESKD) patients, yet comprehensive long-term safety data are lacking. This study leverages the FDA Adverse Event Reporting System (FAERS) to assess the extended safety profile of lanthanum carbonate. RESEARCH DESIGN AND METHODS: We analyzed FAERS data (2004-2022) to study the association between lanthanum carbonate and adverse events (AEs). Using MedDRA v25...
April 11, 2024: Expert Opinion on Drug Safety
Xiaolin Yun, Yingying Zhou, Danna Wu, Yuanbo Liu, Qiongshi Wu
BACKGROUND: Daratumumab, a first-in-class humanized IgG1κ monoclonal antibody that targets the CD38 epitope, has been approved for treatment of multiple myeloma by FDA. The current study was to evaluate daratumumab-related adverse events (AEs) through data mining of the US Food and Drug Administration Adverse Event Reporting System (FAERS). RESEARCH DESIGN AND METHODS: Disproportionality analyses, including the reporting odds ratio (ROR), the proportional reporting ratio (PRR), the Bayesian confidence propagation neural network (BCPNN) and the multi-item gamma Poisson shrinker (MGPS) algorithms were employed to quantify the signals of daratumumab-associated AEs...
April 10, 2024: Expert Opinion on Drug Safety
Harriet Aprilia Dickinson, Jan Feifel, Katoo Muylle, Taichi Ochi, Enriqueta Vallejo-Yagüe
Artificial intelligence or machine learning (AI/ML) based systems can be used to help personalize prescribing decisions for individual patients. These AI/ML clinical decision support systems may provide either specific or more open-ended recommendations for the most appropriate medications to prescribe. These systems must fundamentally relate to the label of the medicines involved. The label of a medicine is an approved guide that indicates how to prescribe the drug in a safe and effective manner. The label for a medicine may evolve as new information on safety and effectiveness emerges, leading to the addition or removal of warnings, drug-drug interactions, or to permit new indications...
April 10, 2024: Expert Opinion on Drug Safety
Khushboo Bisht, Bharathi Mohan, Basavaraj Jatteppanavar, Hannah Theresa Sony, Shailendra Handu, Minakshi Dhar
INTRODUCTION: Medication errors are inherent in a healthcare system. This results in both time and cost burdens for both the patient and the health system. The aim of this study was to conduct a root-cause analysis of medication errors in elderly patients with methotrexate toxicity, analyze associated factors, and propose solutions. METHODS: This single-center prospective study was designed to identify medication errors in cases of methotrexate toxicity between November 2022 to May 2023...
April 4, 2024: Expert Opinion on Drug Safety
Xianlin Li, Nan Shang, Qianci Yan, Xiunan Yue, Yang Liu, Xiaojun Zheng
BACKGROUND: This study analyzed the bleeding adverse events (AEs) resulting from the treatment of B-cell lymphoma with Bruton tyrosine kinase (BTK) inhibitors, according to reports in the US Food and Drug Administration's Adverse Event Reporting System (FAERS). METHODS: Bleeding AEs associated with BTK inhibitors (including ibrutinib, zanubrutinib, and acalabrutinib) from the first quarter of 2013 to the third quarter of 2023 were extracted. Reporting odds ratio (ROR) and proportional reporting ratio (PRR) were reported...
April 3, 2024: Expert Opinion on Drug Safety
Weichui Zhang, Mianhai Chen, Xiaolin Cai, Mengting Zhang, Mianda Hu, Yanghui Hu, Yurong Yang, Jinfeng Zhu, Yikuan Du, Chun Yang
BACKGROUND: Despite its widespread use, the adverse effects (AEs) of memantine have not been well documented, and there is a need to find new ways to analyze the AEs of memantine. RESEARCH DESIGN AND METHODS: AEs in which the primary suspected drug was memantine were retrieved from the FAERS database. The proportional report ratio (PRR), reporting odds ratio (ROR), Bayesian confidence propagation neural network (BCPNN), and empirical Bayesian geometric mean (EBGM) were used to detect potential positive signals between memantine and AEs...
April 3, 2024: Expert Opinion on Drug Safety
Minghui Sun, Qian Cheng, Xuan Shi, Yazheng Zhao, Shupeng Zou
OBJECTIVES: To explore the association between palbociclib and related adverse events (AEs) in the real world through U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) database. METHODS: The signal strength of palbociclib-related AEs was done by disproportionality analysis. Clinical priority of palbociclib-related AEs was scored and ranked by assessing five different features. Serious and non-serious cases were compared by Mann-Whitney U test or Chisquared (χ2 ) test...
April 2, 2024: Expert Opinion on Drug Safety
Irina Luzko, Olga P Nyssen, Leticia Moreira, Javier P Gisbert
INTRODUCTION: Helicobacter pylori (H. pylori), the most prevalent chronic infection globally, is the major cause of relevant diseases such as gastric cancer, leading to high morbidity and mortality worldwide. Several studies have focused on optimize H. pylori eradication treatment through combination therapies and antibiotic resistance. However, the adverse events profile and its impact, as a primary outcome, remains underexplored.The aim of this review was to summarize the available data on the safety of the most common regimens for H...
April 1, 2024: Expert Opinion on Drug Safety
Mengting Chen, Zhichao He, Jianhong Zhu, Shan Yang, Siyuan Gao, Jie Wu, Huaying Ren, Dan Liang, Wei Jiang, Ying Zou, Xiaoxia Yu, Junyan Wu
OBJECTIVES: To investigate the risk of hemorrhage associated with Immune Checkpoint Inhibitors (ICIs) and characterize its clinical features. METHODS: We systematically reviewed randomized clinical trials (RCTs) of hemorrhage related to ICIs and calculated odds ratios (ORs) with 95% confidence intervals (CIs). Pharmacovigilance studies were conducted by collecting ICIs-related hemorrhage cases from the FAERS database and assessing disproportionalities by reporting odds ratios (RORs) and information components (ICs)...
March 31, 2024: Expert Opinion on Drug Safety
Dehua Zhao, Xiaoqing Long, Jisheng Wang
BACKGROUND: To data, there is insufficient large-scale data on the adverse events (AEs) of pemigatinib. Consequently, we conducted a pharmacovigilance study utilizing the Food and Drug Administration Adverse Event Reporting System (FAERS) database to investigate these AEs. RESEARCH DESIGN AND METHODS: The OpenVigil 2.1 was used to extract AE data from the FAERS database. Proportional reporting ratio (PRR), reporting odds ratios (ROR), and bayesian analysis confidence propagation neural network (BCPNN) were used to assess the association between pemigatinib and AEs...
March 29, 2024: Expert Opinion on Drug Safety
Giovanni Corona, Giulia Rastrelli, Clotilde Sparano, Valeria Carinci, Gianni Casella, Linda Vignozzi, Alessandra Sforza, Mario Maggi
INTRODUCTION: The cardiovascular (CV) safety of testosterone (T) replacement therapy (TRT) is still conflicting. Recent data suggested a TRT-related increased risk of atrial fibrillation (AF). To systematic review and meta-analyze CV risk related to TRT as derived from placebo controlled randomized trials (RCTs). AREAS COVERED: An extensive Medline, Embase and Cochrane search was performed. All placebo-controlled RCTs reporting data on TRT-related CV safety were considered...
March 29, 2024: Expert Opinion on Drug Safety
Ahmad Z Al Meslamani
No abstract text is available yet for this article.
March 29, 2024: Expert Opinion on Drug Safety
Juan-Juan Li, Li Chen, Yang Zhao, Xue-Qin Yang, Fa-Bin Hu, Li Wang
OBJECTIVE: The purpose of this study aimed to explore the new and serious adverse events(AEs) of Tacrolimus(FK506), cyclosporine(CsA), azathioprine(AZA), mycophenolate mofetil(MMF), cyclophosphamide(CTX) and methotrexate(MTX), which have not been concerned. METHODS: The FAERS data from January 2016 and December 2022 were selected for disproportionality analysis to discover the potential risks of traditional immunosuppressive drugs. RESULTS: Compared with CsA, FK506 has more frequent transplant rejection, and is more related to renal impairment, COVID-19, cytomegalovirus infection and aspergillus infection...
March 27, 2024: Expert Opinion on Drug Safety
Roger S McIntyre
No abstract text is available yet for this article.
March 23, 2024: Expert Opinion on Drug Safety
Kangyuan Guo, Ganyi Wang, Li Zhang, Zhanchun Feng, Xudong Xia, Xiaobo Sun, Ziqi Yan, Zhiming Jiao, Da Feng
BACKGROUND: Hemorrhage represents the most common and serious side effect of antithrombotic agents. Many studies have compared the risk of bleeding between different antithrombotic agents, but analysis of time-to-onset for hemorrhage induced by these drugs is yet sparse. METHODS: We conducted a retrospective study based on the adverse drug reaction reports on antithrombotic agents collected by the Henan Adverse Drug Reaction Monitoring Center. We assessed the reporting odds ratio to determine the disproportionate reporting signals for bleeding and the Weibull shape parameter was used to evaluate the time-to-onset data...
March 18, 2024: Expert Opinion on Drug Safety
Sichun Xiang, Rongbin Shen, Jingjing Xiang, Ni Zhu, Jianyou Gu, Jianping Shen, Yu Zhang, Hangping Ge
BACKGROUND: Bruton's tyrosine kinase inhibitors (BTKis) are targeted treatments for B-cell tumors but have significant side effects. This study assesses and contrasts the side effects of BTKis alone and its four combination therapies. RESEARCH DESIGN AND METHODS: The reporting odds ratio (ROR) was used to analyze the data on three BTKis monotherapies and combinations of ibrutinib with rituximab, obinutuzumab, venetoclax, and lenalidomide in the FDA Adverse Event Reporting System (FAERS) database up to December 2022...
March 18, 2024: Expert Opinion on Drug Safety
Deniz Özmen, Duygu Demet Alpaydın, Muhammed Ali Saldoğan, Ahmet Emre Eşkazan
INTRODUCTION: Since the introduction of first tyrosine kinase inhibitor(TKI) imatinib, treatment of chronic myeloid leukemia (CML) has reachedexcellent survival expectancies. Long survival rates bring about issuesregarding TKI safety. AREAS COVERED: The aim of this review is to compare the side effectsof current TKIs both in the first- and later lines and outline a safety andprofile of CML treatment. Seminal studies on TKIs and other newer drugs andextended follow-up of these studies, real-life data of each drug were usedduring the course of this...
March 14, 2024: Expert Opinion on Drug Safety
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.